Current Environment:

Gulraiz Chaudry | Medical Services

Programs & Services

Languages

  • English
  • Hindi
  • Urdu

Gulraiz Chaudry | Education

Medical School

University of Edinburgh

1996, Edinburgh, Scotland

Residency

Royal Victoria Infirmary and Freeman Hospitals

2000, Newcastle upon Tyne, England, United Kingdom

Residency

University of Birmingham

2004, Birmingham, England, United Kingdom

Fellowship

Pediatric Radiology

The Hospital for Sick Children

2005, Toronto, Ontario, Canada

Fellowship

Pediatric Interventional Radiology

The Hospital for Sick Children

2006, Toronto, Ontario, Canada

Gulraiz Chaudry | Certifications

  • American Board of Radiology (Diagnostic Radiology)

Gulraiz Chaudry | Professional History

Gulraiz Chaudry, MBChB, is a pediatric interventional radiologist at Boston Children's Hospital. Dr. Chaudry graduated from the University of Edinburgh Medical School and completed residencies in pediatrics and radiology in the UK. These were followed by 2 years of fellowship, 1 in pediatric radiology and 1 in pediatric interventional radiology, both completed at The Hospital for Sick Children in Toronto, Canada. He has been on staff at Boston Children's Hospital since 2006.

Dr. Chaudry is director of the Vascular and Interventional Radiology Fellowship Program at Boston Children’s Hospital.  He serves on pediatric interventional radiology and the student and resident committees of the Society of Interventional Radiology and the pediatric examination committee of the American Board of Radiology.

His primary clinical and research interests are the imaging and interventional treatment of vascular anomalies. He introduced intralesional bleomycin sclerotherapy in Boston, which is used to treat microcystic lymphatic malformations and vascular anomalies of the airway and orbit. He identified the imaging features that differentiate lymphatic anomalies of bone, with significant implications for prognosis and treatment. Currently, in partnership with the Wyss Institute, he is working on the development of a new vascular embolic agent.

Gulraiz Chaudry | Publications